Advances in the understanding of the molecular pathology of the two types of endometrial carcinoma have underpinned the first steps in the development and testing of targeted therapies. This Review discusses the therapeutic targets, molecular diversity of tumors, oncogene addiction and synthetic lethality in this hard-to-treat disease.
- Konstantin J. Dedes
- Daniel Wetterskog
- Jorge S. Reis-Filho
